Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma.

ABSTRACT: Background: Although programmed death-1 (PD-1) blockade is effective in treating several types of cancer, the efficacy of this agent in glioblastoma (GBM) is largely unknown. Methods: We evaluated therapeutic effects of anti-PD-1, temozolomide (TMZ), and their combination in an orthotopic murine GBM model. The phenotype, number, and composition of lymphocytes were evaluated using flow cytometry. Transcriptional profiles of tumor tissues were analyzed using microarrays. Generation of antitumor immunological memory was investigated upon rechallenge. Results: Combined treatment with anti-PD-1 and TMZ yielded synergistic antitumor efficacy in the presence of donor-originated PD-1⁺CD8⁺ T cells in vitro, necessitating in vivo validation. W

SUBMITTER: Park J 

PROVIDER: S-EPMC6287793 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature